Cargando…
Is there a danger of “biocreep” with non-inferiority trials?
Autores principales: | Beryl, Primrose, Vach, Werner |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287743/ http://dx.doi.org/10.1186/1745-6215-12-S1-A29 |
Ejemplares similares
-
Potential role of “the compensating benefit” in claiming non-inferiority
por: Beryl, Primrose, et al.
Publicado: (2013) -
A framework to assess the impact of applying formal criteria to check clinical relevance on top of statistical significance
por: Vach, Werner, et al.
Publicado: (2013) -
Choice of Non-Inferiority (NI) Margins Does Not Protect against Degradation of Treatment Effects on an Average – An Observational Study of Registered and Published NI Trials
por: Gladstone, Beryl Primrose, et al.
Publicado: (2014) -
Symptoms, dangerousness and involuntary admission
por: Mulder, Cornelis L
Publicado: (2007) -
The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs
por: Phillips, Patrick PJ, et al.
Publicado: (2011)